Skip to main content
Top
Published in: The journal of nutrition, health & aging 8/2011

01-10-2011 | JNHA: Frailty and Cognitive Decline

Rapid cognitive decline, one-year institutional admission and one-year mortality: Analysis of the ability to predict and inter-tool agreement of four validated clinical frailty indexes in the safes cohort

Authors: M. Drame, J. -L. Novella, D. Jolly, I. Laniece, D. Somme, D. Heitz, J. -B. Gauvain, T. Voisin, B. De Wazieres, R. Gonthier, C. Jeandel, P. Couturier, O. Saint-Jean, J. Ankri, F. Blanchard, Pierre Olivier Lang

Published in: The journal of nutrition, health & aging | Issue 8/2011

Login to get access
Metadata
Title
Rapid cognitive decline, one-year institutional admission and one-year mortality: Analysis of the ability to predict and inter-tool agreement of four validated clinical frailty indexes in the safes cohort
Authors
M. Drame
J. -L. Novella
D. Jolly
I. Laniece
D. Somme
D. Heitz
J. -B. Gauvain
T. Voisin
B. De Wazieres
R. Gonthier
C. Jeandel
P. Couturier
O. Saint-Jean
J. Ankri
F. Blanchard
Pierre Olivier Lang
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
The journal of nutrition, health & aging / Issue 8/2011
Print ISSN: 1279-7707
Electronic ISSN: 1760-4788
DOI
https://doi.org/10.1007/s12603-011-0164-8

Other articles of this Issue 8/2011

The journal of nutrition, health & aging 8/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine